These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3940631)

  • 1. Increased therapeutic benefit through the addition of misonidazole to a nitrosourea-radiation combination.
    Siemann DW; Hill SA
    Cancer Res; 1986 Feb; 46(2):629-32. PubMed ID: 3940631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
    Siemann DW; Morrissey S; Wolf K
    Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice.
    Siemann DW; Maddison K; Wolf K; Hill SA; Keng PC
    Cancer Res; 1985 Jan; 45(1):198-202. PubMed ID: 3965132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
    Siemann DW; Alliet K; Maddison K; Wolf K
    Cancer Treat Rep; 1985 Dec; 69(12):1409-14. PubMed ID: 3841024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
    Hirst DG; Brown JM; Hazlehurst JL
    Cancer Res; 1983 May; 43(5):1961-5. PubMed ID: 6682009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemopotentiation in vivo: no loss of sensitization with fractionation.
    Hill SA; Siemann DW
    Br J Cancer; 1984 Oct; 50(4):509-17. PubMed ID: 6487517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced tumor responses through therapies combining CCNU, MISO and radiation.
    Siemann DW; Hill SA
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1623-6. PubMed ID: 6480451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of CCNU, MISO, and fractionated radiotherapy.
    Siemann DW; Alliet KL
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1379-82. PubMed ID: 3759559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of combination chemotherapy by nitroheterocyclics.
    Siemann DW; Allalunis-Turner MJ
    Int J Radiat Oncol Biol Phys; 1988 Jul; 15(1):129-34. PubMed ID: 3391809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus misonidazole.
    Milas L; Ito H; Nakayama T; Hunter N
    Cancer Res; 1991 Jul; 51(14):3639-42. PubMed ID: 2065321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dose relationships for simultaneous misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea exposures in vitro.
    Mulcahy RT; Dembs N
    Cancer Res; 1983 Aug; 43(8):3539-43. PubMed ID: 6861127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Misonidazole-induced chemopotentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea toxicity in O6-methylguanine-DNA methyltransferase proficient (Mer+) and deficient (Mer-) cell lines.
    Mulcahy RT
    Cancer Res; 1986 Jun; 46(6):2892-7. PubMed ID: 3698015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of CCNU activity by misonidazole in metastases.
    Siemann DW; Alliet KL
    Clin Exp Metastasis; 1987; 5(1):57-63. PubMed ID: 3829497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pretreatment with phenobarbital or SKF 525A on the toxicity and antitumor activity of lomustine.
    Siemann DW
    Cancer Treat Rep; 1983 Mar; 67(3):259-65. PubMed ID: 6831472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.
    Clement JJ; Gorman MS; Wodinsky I; Catane R; Johnson RK
    Cancer Res; 1980 Nov; 40(11):4165-72. PubMed ID: 7471058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW
    Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
    Grégoire V; Hunter N; Milas L; Brock WA; Plunkett W; Hittelman WN
    Cancer Res; 1994 Jan; 54(2):468-74. PubMed ID: 8275483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses of tumor cell subpopulations to single modality and combined modality therapies.
    Siemann DW; Keng PC
    NCI Monogr; 1988; (6):101-5. PubMed ID: 3127731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.